Skip to main content
Thorax logoLink to Thorax
. 1984 Oct;39(10):726–732. doi: 10.1136/thx.39.10.726

Serum type III procollagen peptide concentration in cryptogenic fibrosing alveolitis and its clinical relevance.

J M Kirk, E D Bateman, P L Haslam, G J Laurent, M Turner-Warwick
PMCID: PMC459910  PMID: 6495240

Abstract

The serum concentrations of a metabolite produced during synthesis type III collagen, type III procollagen peptide (PCP), were measured in patients with cryptogenic fibrosing alveolitis, and the results were related to the course of the disease and its response to treatment. The mean PCP concentration was significantly higher for patients untreated at the time of sampling than for an age and sex matched control group (p less than 0.001). Seventeen of these patients subsequently started treatment and their response to treatment was assessed by measurement of changes in the transfer coefficient (KCO) and forced vital capacity (FVC) at six months and one year later. Those patients showing a response to treatment, indicated by an increase in the percentage predicted KCO or FVC of more than 10% one year after starting treatment, had a significantly higher mean PCP concentration (p less than 0.01 and p less than 0.001 respectively) than patients with stable or deteriorating physiological indices. When the PCP concentrations of these patients were compared with repeat measurements three to six months after the commencement of treatment 14 out of 17 showed a decrease in PCP levels. This percentage change in PCP concentrations correlated significantly with the change in the percentage predicted KCO and FVC at 12 months after the commencement of treatment (p less than 0.01). These results suggest that measurement of PCP concentrations in patients with cryptogenic fibrosing alveolitis may be useful in the assessment of response to treatment.

Full text

PDF
726

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bateman E. D., Turner-Warwick M., Haslam P. L., Adelmann-Grill B. C. Cryptogenic fibrosing alveolitis: prediction of fibrogenic activity from immunohistochemical studies of collagen types in lung biopsy specimens. Thorax. 1983 Feb;38(2):93–101. doi: 10.1136/thx.38.2.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Clark J. G., Overton J. E., Marino B. A., Uitto J., Starcher B. C. Collagen biosynthesis in bleomycin-induced pulmonary fibrosis in hamsters. J Lab Clin Med. 1980 Dec;96(6):943–953. [PubMed] [Google Scholar]
  3. Crystal R. G., Fulmer J. D., Roberts W. C., Moss M. L., Line B. R., Reynolds H. Y. Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med. 1976 Dec;85(6):769–788. doi: 10.7326/0003-4819-85-6-769. [DOI] [PubMed] [Google Scholar]
  4. Cutroneo K. R., Rokowski R., Counts D. F. Glucocorticoids and collagen synthesis: comparison of in vivo and cell culture studies. Coll Relat Res. 1981 Nov;1(6):557–568. doi: 10.1016/s0174-173x(81)80037-4. [DOI] [PubMed] [Google Scholar]
  5. Fessler J. H., Fessler L. I. Biosynthesis of procollagen. Annu Rev Biochem. 1978;47:129–162. doi: 10.1146/annurev.bi.47.070178.001021. [DOI] [PubMed] [Google Scholar]
  6. Fulmer J. D., Bienkowski R. S., Cowan M. J., Breul S. D., Bradley K. M., Ferrans V. J., Roberts W. C., Crystal R. G. Collagen concentration and rates of synthesis in idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1980 Aug;122(2):289–301. doi: 10.1164/arrd.1980.122.2.289. [DOI] [PubMed] [Google Scholar]
  7. Haschek W. M., Klein-Szanto A. J., Last J. A., Reiser K. M., Witschi H. Long-term morphologic and biochemical features of experimentally induced lung fibrosis in the mouse. Lab Invest. 1982 Apr;46(4):438–449. [PubMed] [Google Scholar]
  8. Haslam P. L., Turton C. W., Heard B., Lukoszek A., Collins J. V., Salsbury A. J., Turner-Warwick M. Bronchoalveolar lavage in pulmonary fibrosis: comparison of cells obtained with lung biopsy and clinical features. Thorax. 1980 Jan;35(1):9–18. doi: 10.1136/thx.35.1.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kirk J. M., Heard B. E., Kerr I., Turner-Warwick M., Laurent G. J. Quantitation of types I and III collagen in biopsy lung samples from patients with cryptogenic fibrosing alveolitis. Coll Relat Res. 1984 May;4(3):169–182. doi: 10.1016/s0174-173x(84)80039-4. [DOI] [PubMed] [Google Scholar]
  10. Laurent G. J., Cockerill P., McAnulty R. J., Hastings J. R. A simplified method for quantitation of the relative amounts of type I and type III collagen in small tissue samples. Anal Biochem. 1981 May 15;113(2):301–312. doi: 10.1016/0003-2697(81)90081-6. [DOI] [PubMed] [Google Scholar]
  11. Laurent G. J., McAnulty R. J., Corrin B., Cockerill P. Biochemical and histological changes in pulmonary fibrosis induced in rabbits with intratracheal bleomycin. Eur J Clin Invest. 1981 Dec;11(6):441–448. doi: 10.1111/j.1365-2362.1981.tb02011.x. [DOI] [PubMed] [Google Scholar]
  12. Laurent G. J., McAnulty R. J. Protein metabolism during bleomycin-induced pulmonary fibrosis in rabbits. In vivo evidence for collagen accumulation because of increased synthesis and decreased degradation of the newly synthesized collagen. Am Rev Respir Dis. 1983 Jul;128(1):82–88. doi: 10.1164/arrd.1983.128.1.82. [DOI] [PubMed] [Google Scholar]
  13. Laurent G. J. Rates of collagen synthesis in lung, skin and muscle obtained in vivo by a simplified method using [3H]proline. Biochem J. 1982 Sep 15;206(3):535–544. doi: 10.1042/bj2060535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Low R. B., Cutroneo K. R., Davis G. S., Giancola M. S. Lavage type III procollagen N-terminal peptides in human pulmonary fibrosis and sarcoidosis. Lab Invest. 1983 Jun;48(6):755–759. [PubMed] [Google Scholar]
  15. Nowack H., Olsen B. R., Timpl R. Characterization of the amino-terminal segment in type III procollagen. Eur J Biochem. 1976 Nov 1;70(1):205–216. doi: 10.1111/j.1432-1033.1976.tb10971.x. [DOI] [PubMed] [Google Scholar]
  16. Reiser K. M., Hesterberg T. W., Haschek W. M., Last J. A. Experimental silicosis. I. Acute effects of intratracheally instilled quartz on collagen metabolism and morphologic characteristics of rat lungs. Am J Pathol. 1982 May;107(2):176–185. [PMC free article] [PubMed] [Google Scholar]
  17. Reiser K. M., Last J. A. Pulmonary fibrosis in experimental acute respiratory disease. Am Rev Respir Dis. 1981 Jan;123(1):58–63. doi: 10.1164/arrd.1981.123.1.58. [DOI] [PubMed] [Google Scholar]
  18. Rohde H., Vargas L., Hahn E., Kalbfleisch H., Bruguera M., Timpl R. Radioimmunoassay for type III procollagen peptide and its application to human liver disease. Eur J Clin Invest. 1979 Dec;9(6):451–459. doi: 10.1111/j.1365-2362.1979.tb00912.x. [DOI] [PubMed] [Google Scholar]
  19. Seyer J. M., Hutcheson E. T., Kang A. H. Collagen polymorphism in idiopathic chronic pulmonary fibrosis. J Clin Invest. 1976 Jun;57(6):1498–1507. doi: 10.1172/JCI108420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Stack B. H., Choo-Kang Y. F., Heard B. E. The prognosis of cryptogenic fibrosing alveolitis. Thorax. 1972 Sep;27(5):535–542. doi: 10.1136/thx.27.5.535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Taubman M. B., Kammerman S., Goldberg B. Radioimmunoassay of procollagen in serum of patients with Paget's disease of bone. Proc Soc Exp Biol Med. 1976 Jun;152(2):284–287. doi: 10.3181/00379727-152-39380. [DOI] [PubMed] [Google Scholar]
  22. Turner-Warwick M., Burrows B., Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax. 1980 Mar;35(3):171–180. doi: 10.1136/thx.35.3.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Turner-Warwick M., Haslam P. Antibodies in some chronic fibrosing lung diseases. I. Non organ-specific autoantibodies. Clin Allergy. 1971 Mar;1(1):83–95. doi: 10.1111/j.1365-2222.1971.tb02450.x. [DOI] [PubMed] [Google Scholar]
  24. Winterbauer R. H., Hammar S. P., Hallman K. O., Hays J. E., Pardee N. E., Morgan E. H., Allen J. D., Moores K. D., Bush W., Walker J. H. Diffuse interstitial pneumonitis. Clinicopathologic correlations in 20 patients treated with prednisone/azathioprine. Am J Med. 1978 Oct;65(4):661–672. doi: 10.1016/0002-9343(78)90855-0. [DOI] [PubMed] [Google Scholar]
  25. Wright P. H., Heard B. E., Steel S. J., Turner-Warwick M. Cryptogenic fibrosing alveolitis: assessment by graded trephine lung biopsy histology compared with clinical, radiographic, and physiological features. Br J Dis Chest. 1981 Jan;75(1):61–70. doi: 10.1016/s0007-0971(81)80008-3. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES